CBFB and acute myeloid leukemia: Guido Marcucci from Ohio reported on the initial results of the CALGB 10801 (Alliance) multicentre study, and showed non-inferiority in terms of toxicity and remission rates of adding the KIT inhibitor dasatinib to standard induction and consolidation therapy for CBFb mutated AML.